e-learning
resources
Paris 2018
Monday, 17.09.2018
CTD-ILD and hypersensitivity pneumonitis: mechanistic insights and prognostic markers
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Diagnostic value of serum KL-6 in Interstitial Lung Disease: preliminary results from an European cohort.
P. Millan Billi (Barcelona, Spain), I. Castellví (Barcelona, Spain), L. Martinez Martinez (Barcelona, Spain), F. Aparicio (Barcelona, Spain), T. Franquet (Barcelona, Spain), O. Sibila Vidal (Barcelona, Spain), D. Castillo Villegas (Barcelona, Spain)
Source:
International Congress 2018 – CTD-ILD and hypersensitivity pneumonitis: mechanistic insights and prognostic markers
Session:
CTD-ILD and hypersensitivity pneumonitis: mechanistic insights and prognostic markers
Session type:
Thematic Poster
Number:
2959
Disease area:
Interstitial lung diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
P. Millan Billi (Barcelona, Spain), I. Castellví (Barcelona, Spain), L. Martinez Martinez (Barcelona, Spain), F. Aparicio (Barcelona, Spain), T. Franquet (Barcelona, Spain), O. Sibila Vidal (Barcelona, Spain), D. Castillo Villegas (Barcelona, Spain). Diagnostic value of serum KL-6 in Interstitial Lung Disease: preliminary results from an European cohort.. 2959
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
The Relationship Between Functional Status and Fatigue After COVID-19 Infection
Definition and history of sarcoidosis
Evidence of early abnormal airways’ inflammation in children with type 1 diabetes
Related content which might interest you:
Value of community based Pulmonary Rehabilitation (PR) for patients with Interstitial Lung Disease (ILD): A retrospective review
Source: International Congress 2019 – Pulmonary rehabilitation for non-obstructive lung diseases
Year: 2019
Assessing sarcoidosis activity: Is serum chitotriosidase a reliable marker? Study of 430 patients and 264 healthy controls
Source: International Congress 2014 – Pathogenetic mechanisms in pulmonary fibrosis
Year: 2014
Romanian Registry for Interstitial Lung Diseases (REGIS): inclusion of patients in 3 years
Source: International Congress 2017 – ILDs: clinical problems
Year: 2017
Analysis of children’s diffuse parenchymal lung disease from the European Management Platform for Childhood Interstitial Lung Diseases: Frequency of disease categories and treatments used
Source: International Congress 2017 – Rare diseases
Year: 2017
Gender perspective in Interstitial Lung Diseases (ILD)
Source: International Congress 2019 – The changing face of rare diffuse parenchymal lung diseases: recent advances in pathogenesis, clinical manifestations and treatment
Year: 2019
Treatment of IPF with inhaled IFN-gamma; planning for a clinical trial
Source: International Congress 2014 – ILDs 3
Year: 2014
Combined pulmonary fibrosis and emphysema: A report from the Hellenic Interstitial Lung Diseases group
Source: Annual Congress 2010 - Different patterns of interstitial lung disease
Year: 2010
Anti-synthetase syndrome associated Interstitial Lung Disease (ASS-ILD): Clinical, serological and radiological heterogeneity
Source: International Congress 2017 – The spectrum of CTDs: from pathogenesis to treatment
Year: 2017
Prognostic and predictive value of E-cathepsin for pulmonary adenocarcinomas in the IALT (International Adjuvant Lung Cancer Trial)
Source: Annual Congress 2006 - Prognostic factors in lung cancer
Year: 2006
The impact of the new Global Lung Function Initiative
T
LCO
reference values on trial inclusion for patients with idiopathic pulmonary fibrosis
Source: Eur Respir J, 53 (2) 1801895; 10.1183/13993003.01895-2018
Year: 2019
Translation and preliminary validation of the KBILD QOL questionnaire to Spanish
Source: International Congress 2014 – ILDs 6
Year: 2014
Translation and validation of the King's brief interstitial lung disease (K-BILD) questionnaire in French, Italian and Dutch
Source: International Congress 2014 – ILDs 2
Year: 2014
Lung cancer after lymphoma: Disease characteristics, detection methods and clinical outcome
Source: Annual Congress 2013 –Other thoracic tumours, particular circumstances and rare cases
Year: 2013
Lung cancer screening in COPD patients: NLST criteria vs a COPD screening score
Source: International Congress 2014 – The assessment of comorbidities
Year: 2014
Verification of genetic associations with Scleroderma associated Interstitial Lung Disease
Source: International Congress 2019 – From biomarkers to treatment of immune-mediated interstitial lung disease: what’s new?
Year: 2019
Hospitalisation pattern in Interstitial Lung Diseases: a claims data study
Source: International Congress 2018 – Consequences of idiopathic interstitial pneumonias
Year: 2018
Sputum YKL-40 is a potential biomarker of COPD-asthma overlap
Source: International Congress 2014 – Systemic and airway biomarkers
Year: 2014
Diagnostic contribution of EBUS in Interstitial Lung Desease (excluding Sarcoidosis)
Source: International Congress 2018 – Idiopathic interstital pneumonias other than idiopathic pulmonary fibrosis (IPF)
Year: 2018
MUC1 gene polymorphism and serum KL-6 in lung adenocarcinoma
Source: International Congress 2015 – Lung cancer: prognostic factors and features of oncogene-driven tumours
Year: 2015
Validation of the LENT score in Japanese sample: The impact of EGFR-TKI
Source: International Congress 2015 – Mediastinal tumors, malignant pleural mesothelioma and other rare tumors
Year: 2015
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept